Latest Regulatory Approvals News

National Storage REIT has received a conditional, non-binding proposal from a Brookfield and GIC consortium to acquire all stapled securities at $2.86 each, triggering an exclusivity period for negotiations.

InhaleRX Limited has announced a non-renounceable entitlement offer to raise approximately $247,668 by issuing nearly 10 million new shares at 2.5 cents each, accompanied by free attaching options. The offer opens on 5 December and closes on 17 December 2025.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Santa Fe Minerals has struck a binding deal to acquire an 80% stake in four gold projects in Côte d’Ivoire, backed by a $6 million placement. The acquisition expands its footprint in West Africa’s prolific gold belt, offering a robust pipeline from early-stage prospects to drill-ready targets.

Santa Fe Minerals Limited has agreed to acquire an 80% stake in four promising gold projects in Côte d’Ivoire, backed by a $6 million placement to accelerate exploration. The deal significantly broadens Santa Fe’s presence in a prolific West African gold region.

Invictus Energy updates progress on its AMOG joint venture with Al Mansour Holdings, revealing ongoing negotiations for a significant Qatari ownership stake and deferral of a key placement settlement.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Sarytogan Graphite Limited has raised $1.8 million through a placement to fund its Definitive Feasibility Study and advance key project development activities at its strategic graphite deposit in Kazakhstan.

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.

Mammoth Minerals has identified a major new 5.5km by 4.2km intrusive complex at its Excelsior Gold Project in Nevada, drawing parallels to the prolific 4.2Moz Goldfield Caldera. Concurrent surveys at its Skyline Project in Canada bolster its base metals exploration pipeline, while plans for a strategic spinout are underway.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.